Shanghai Kexin Biopharmaceutical Technology

Shanghai Kexin Biopharmaceutical Technology is a Chinese biotechnology company specializing in the development of innovative biological drugs and diagnostic reagents. Founded in 2008 and headquartered in Shanghai, the company focuses on therapeutic areas such as immunology, respiratory diseases, and oncology. Its lead drug candidate, JZB-34 (also known as AAFP), is a recombinant human IgE and IgG Fc fusion protein currently in Phase 1 clinical trials for the treatment of hypersensitivity and asthma. Additionally, the company develops a range of in vitro diagnostic products using platforms like colloidal gold and enzyme-linked immunosorbent assays (ELISA). Through its acquisition of Kinghawk Technology, the company has strengthened its position in the diagnostic market while continuing to leverage its protein engineering expertise to address unmet medical needs in immune-mediated conditions.